Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia. - Test2 - elhamkhani - TriplyDB

Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.

Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.

http://www.wikidata.org/entity/Q34933267

about

Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications Single or 2-Dose Micafungin Regimen for Treatment of Invasive Candidiasis: Therapia Sterilisans Magna!Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study.Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy.Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model.Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people.Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths.Serum drug concentrations predictive of pulmonary tuberculosis outcomes.Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.Comparative Population Plasma and Tissue Pharmacokinetics of Micafungin in Critically Ill Patients with Severe Burn Injuries and Patients with Complicated Intra-Abdominal Infection Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections.Micafungin Plasma Levels Are Not Affected by Continuous Renal Replacement Therapy: Experience in Critically Ill Patients.Impact of special patient populations on the pharmacokinetics of echinocandins.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis.Micafungin: A Review in the Prophylaxis and Treatment of Invasive Candida Infections in Paediatric Patients.Caspofungin exposure-response relationships in adult patients with mucosal or invasive candidiasis.The Role of In Vitro Susceptibility Testing in the Management of Candida and Aspergillus.Clinical Pharmacokinetics and Pharmacodynamics of Micafungin.Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation.Efficacy of Extended-Interval Dosing of Micafungin Evaluated Using a Pharmacokinetic/Pharmacodynamic Study with Humanized Doses in Mice.Optimal doses of caspofungin during continuous venovenous hemodiafiltration in critically ill patients The EMPIRICUS trial-the final nail in the coffin of empirical antifungal therapy in the intensive care unit?EUCAST technical note on Candida and micafungin, anidulafungin and fluconazole.Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model.Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata.Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients.Pharmacological and Host Considerations Surrounding Dose Selection and Duration of Therapy with Echinocandins In silico-derived bedside formula for individualized micafungin dosing for obese patients in the age of deterministic chaos

P2860

Q27025299-E9EB2470-7A92-48D8-A1BC-F25F34D7D0F9 Q28082570-783DE4FE-AC9C-4464-ACA7-C7300EDCCBDA Q30936281-08B0E994-C412-48C9-83AA-975EF1DD22AB Q34298988-22A2E44B-2DB5-4DFC-9705-6242FF7ED852 Q35105763-8A892E95-FDF0-4427-8330-842A22C2FCC0 Q35363785-B05B5C2D-A9C2-48DF-AAFC-1A633D547845 Q35860004-E7E853D3-2BAC-41E2-A2D2-17863BE9BF1B Q36364100-92B66782-A2A3-4EED-80A4-2DADC0B2255D Q36785939-A9271E2D-4AB0-4F1A-9B3A-8D9068A3F255 Q37213037-CF8A4488-621C-4168-B952-659DBE3164CC Q37263435-0CAC36A1-0D1E-445B-A182-D16FD16B8264 Q37287812-3E17D872-5A8F-4959-8FBC-649B9D9EE0A2 Q38053482-E3190B4F-6A14-4FAA-87EA-644D7D8412CF Q38375996-1CF3704A-329B-47D5-9DBD-F183B6EBA373 Q38462784-160FEED7-CE59-4DE9-85D4-A4EAA1634577 Q38681635-B2868846-27A1-4856-8E3E-CB15CF44D06D Q38763496-D3B46237-2D19-447D-B376-4554B667AA45 Q39031509-D2E68E29-9979-47B3-ABC7-FD37C045DAB7 Q39085041-750154FE-07FF-4113-8A72-B21A34AF7016 Q39810663-1B47395D-EE92-458B-83FE-A0728C41C6AA Q40045635-65899720-E71C-4D6D-9514-07E2D943FD04 Q40100873-CEE43424-CE7C-4CFD-893B-17212F4A682E Q40546653-A2DD6DDC-C5D2-406A-BD36-00632EB3400A Q40916536-F2006FF8-466D-49D6-BAEB-C002AC03D215 Q42326553-61DF88FC-A1F6-4AD6-B1E6-280C788BEAC7 Q42362382-278AAC8B-5AE5-41DF-BA2E-2C29E02AAEF5 Q44013179-7F249487-8201-4912-A2DB-8C4A320D5AEC Q47876785-7B3F1F21-6F60-4C1D-A6BE-FA8EA13B2573 Q49598880-E296A1F3-A149-45E9-B57B-0E0FE4B16E4F Q52648077-69BC882D-AF85-4389-8DF1-75F2E490B48C Q53822956-88C07722-106E-43C3-9BFB-C7F37359772B Q57746174-E70CEF22-8C6C-43E3-9ED0-A5A6BC33D921 Q58033439-5FB13E2B-1691-4337-A4E7-BC16DB74DD8A

P2860

Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.

http://www.wikidata.org/entity/Q34933267

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Use of pharmacokinetic-pharmac ...... ive candidiasis or candidemia.

@ast

Use of pharmacokinetic-pharmac ...... ive candidiasis or candidemia.

@en

Use of pharmacokinetic-pharmac ...... ive candidiasis or candidemia.

@nl

type

label

Use of pharmacokinetic-pharmac ...... ive candidiasis or candidemia.

@ast

Use of pharmacokinetic-pharmac ...... ive candidiasis or candidemia.

@en

Use of pharmacokinetic-pharmac ...... ive candidiasis or candidemia.

@nl

prefLabel

Use of pharmacokinetic-pharmac ...... ive candidiasis or candidemia.

@ast

Use of pharmacokinetic-pharmac ...... ive candidiasis or candidemia.

@en

Use of pharmacokinetic-pharmac ...... ive candidiasis or candidemia.

@nl

P1433

Q34933267-1A57047A-C337-4B44-B03F-11B6EEF971FA

P1476

Q34933267-7354DA26-EA80-4E48-9FA9-DBFB543A585F

P2093

Q34933267-1C607341-7850-4F34-9B17-638099F041F2

Q34933267-213FA617-5F79-40CA-8863-15876FC6989C

Q34933267-35E20015-F84E-415D-8794-E88D5EBD444F

Q34933267-3C7C889D-C348-4AAB-8CFD-3D1E83756EB8

Q34933267-3E36D75A-1C15-4C37-B820-226679920313

Q34933267-4151C7D5-A629-4F56-90AA-C1249E5943A4

Q34933267-4850A718-7C1D-41DA-8E4F-ACB4EF7A5E68

Q34933267-89BE4619-4C0B-43C1-86E8-9A2E29F2DA72

Q34933267-EDEC4F58-E2A5-48A6-A597-6A1BC948E3D5

P2860

Q34933267-04B90DE3-F2E7-4B17-9AA8-AEBF80A95AA2

Q34933267-175775AB-A0C3-48D4-BDF5-E4B9428B57B4

Q34933267-17C762BB-477D-4FAE-856A-8AAE8DA65D76

Q34933267-186AAB60-27B6-46AD-B185-C339C79E6CAA

Q34933267-1EB99B00-D92B-4D15-B136-CA8B06A79695

Q34933267-2443A3AE-C390-4312-8010-BB76110237F4

Q34933267-2D28CFCB-7F41-4635-B453-EBBED959C448

Q34933267-2D325A9C-1FD7-4C24-85FC-FE9B463A6B03

Q34933267-2FFA0AFD-AD76-49F4-98A4-7F12B7618FED

Q34933267-3258DFBE-7FB8-4616-9684-D821FEC287F1

P304

Q34933267-F6D3840A-68E8-422B-AEAC-5D15636F93EF

P31

Q34933267-189D59EA-B39C-4FC8-BB31-EE9E4366BC2B

P356

Q34933267-28045D31-735E-4D6E-BF90-45F23BE5EF13

P407

Q34933267-078A6417-B1E4-4ADC-B3E7-A8954853693F

P433

Q34933267-6E6D5594-F758-4CEB-B24D-9872D1A8A9C6

P478

Q34933267-4BA02DFC-4065-461B-AEB4-016DBB36A7EA

P577

Q34933267-54778FCE-A17B-43FC-AE72-B24702AF3B48

P698

Q34933267-6B2A06F5-F015-46F2-8702-17016C18A490

P932

Q34933267-8E49DACF-3E6D-4747-9681-D754B68AE1E0

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Use of pharmacokinetic-pharmac ...... ive candidiasis or candidemia.

@en

P2093

Daniel K Reynolds

http://www.w3.org/2001/XMLSchema#string

David Andes

http://www.w3.org/2001/XMLSchema#string

Donald N Buell

http://www.w3.org/2001/XMLSchema#string

Jeffrey P Hammel

http://www.w3.org/2001/XMLSchema#string

Laura L Kovanda

http://www.w3.org/2001/XMLSchema#string

Paul G Ambrose

http://www.w3.org/2001/XMLSchema#string

Scott A Van Wart

http://www.w3.org/2001/XMLSchema#string

Sujata M Bhavnani

http://www.w3.org/2001/XMLSchema#string

Varsha Iyer

http://www.w3.org/2001/XMLSchema#string

P2860

In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole

Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin

Epidemiology of invasive candidiasis: a persistent public health problem

Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.

Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome

Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.

Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models

Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.

P304

2113-2121

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01430-10

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21300835

http://www.w3.org/2001/XMLSchema#string

P932

3088268

http://www.w3.org/2001/XMLSchema#string